Press Releases — Oncoheroes Biosciences

Press Releases — Oncoheroes Biosciences

Featured

Sep 3, 2024

Oncoheroes Obtains Exclusive Worldwide Oncology Pediatric Rights Of Dovitinib

Sep 3, 2024

Read More →

Sep 3, 2024

Oct 13, 2023

Dovitinib, a potential new treatment for osteosarcoma, receives Orphan Drug Designation from the U.S. FDA

Oct 13, 2023

Read More →

Oct 13, 2023

Oct 2, 2023

FDA Allows Oncoheroes to Begin Two Pediatric Oncology Clinical Trials

Oct 2, 2023

Read More →

Oct 2, 2023

Sep 23, 2022

FDA Grants Rare Pediatric Disease Designation (RPDD) to dovitinib for osteosarcoma

Sep 23, 2022

Read More →

Sep 23, 2022

Jul 14, 2022

Vall d’Hebron Research Institute (VHIR) and Oncoheroes Biosciences to Partner for the Discovery and Development of Novel Therapies for Childhood Sarcomas

Jul 14, 2022

Read More →

Jul 14, 2022

Jan 3, 2022

Oncoheroes Biosciences and Allarity Therapeutics Sign Exclusive Pediatric Licensing Agreement for Dovitinib and Stenoparib

Jan 3, 2022

Read More →

Jan 3, 2022

Nov 11, 2021

Oncoheroes Biosciences Inc. Out-licences volasertib to Notable Labs for the Global Adult Development of Its Anticancer Therapy

Nov 11, 2021

Read More →

Nov 11, 2021

Feb 15, 2021

SHEPHERD Therapeutics and Oncoheroes Biosciences to Partner for the Discovery, Development, and Commercialization of Oncology Therapeutics For Rare Cancers

Feb 15, 2021

Read More →

Feb 15, 2021

Oct 14, 2020

Volasertib, a potential new treatment for rhabdomyosarcoma, receives Orphan Drug Designation from the U.S. FDA

Oct 14, 2020

Read More →

Oct 14, 2020

Sep 24, 2020

FDA Grants Rare Pediatric Disease Designation (RPDD) to volasertib for rhabdomyosarcoma

Sep 24, 2020

Read More →

Sep 24, 2020